DIRS.INFO The most relevant business & tech news

Morgan Stanley cut its price target on Tesla after trimming its profitability forecasts. The analyst has a price target of $500, which implies upside of more than 20% over the next 12 months. — Hakyung Kim 6:51 a.m.: JPMorgan raises CrowdStrike price target after earnings beat CrowdStrike is managing to grow quickly while delivering strong results, says JPMorgan. The bank upgraded the retailer to buy from hold, increasing its price target to $195 from $140. — Fred Imbert 5:40 a.m.: Morgan Stanley cuts Tesla price target 2024 will be for electric vehicles, said Morgan Stanley's Adam Jonas, who warns that Tesla could lose money this year.

Persons: Morgan Stanley, Wells, Andrew Nowinski, MongoDB, Hakyung Kim, CrowdStrike, Brian Essex, Essex, — Hakyung Kim, UnitedHealth, Andrew Mok, Mok, Berenberg, Philip Buller, Buller, Bob Jian Huang, Huang, Daniela Bretthauer, Krisztina Katai, — Fred Imbert, Morgan Stanley's Adam Jonas, Tesla, Jonas Organizations: CNBC, HSBC, Target, JPMorgan, Barclays, Medicare, Honeywell, Berenberg, Morgan Stanley Insurance, Progressive, Target . Deutsche Bank Locations: Andrew Mok ., Honeywell's, U.S, Tuesday's

☆ Stocks with high dividend growth and free cash flow perform best whatever the weather, Wolfe says
▼ + stars: | 2024-03-06 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Stocks that offer high dividend growth and high free cash flow perform best no matter the economic weather, according to Wolfe Research. Here are a few stocks that fit the bill, according to Senyek: Online marketplace eBay was one of several stocks that Wolfe singled out. With its 4% yield, CVS is also a good buy for investors focusing on a high-dividend growth, high free cash flow strategy, Wolfe said. Following CVS' earnings release, investment bank Leerink initiated research coverage of the stock with an outperform rating , citing its cash potential. Other stocks Wolfe included on its list were Constellation Energy , Humana and Archer-Daniels-Midland .

Persons: Chris Senyek, Wolfe, UnitedHealth, Andrew Mok, Tom Cowhey, — CNBC's Michael Bloom Organizations: Wolfe Research, eBay, Barclays, Medicare, CVS, Constellation Energy, Humana, Archer, Daniels, Midland

☆ UBS upgrades this kidney treatment stock, says it could rally 30%
▼ + stars: | 2023-08-07 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Kidney dialysis services company DaVita could soon see a turning point in treatment growth, according to UBS. The analyst forecasts the company could post $9 per share in 2024, which lies between 10% to 18% above other analyst estimates. Dialysis patient growth has improved over the past three quarters following the post-Covid recovery, said Mok. According to Mok, DaVita has outperformed initial earnings guidance in the first half of 2023 owing to multiple tailwinds. The analyst cited higher revenue per treatment, better mortality trends and continued execution on contract labor.

Persons: Andrew Mok, Mok, DaVita, Michael Bloom Organizations: UBS

☆ Stocks making the biggest moves midday: Tesla, Berkshire Hathaway, PayPal, Cinemark and more
▼ + stars: | 2023-08-07 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

The company earned €168 million in revenue, while analysts polled by Refinitiv expected €672 million. The company reported adjusted net income and revenue that beat expectations for the second quarter. Viatris reported revenue of $3.92 billion, while analysts polled by StreetAccount called for $3.86 billion. PayPal – PayPal stock climbed 2% after launching its first stablecoin, PayPal USD, backed by the U.S. dollar on Monday. Analysts polled by FactSet are forecasting an adjusted 5 cents per share on $534.2 million in sales.

Persons: Tesla, Zach Kirkhorn, Vaibhav Taneja, Taneja, BioNTech, Refinitiv, Tyson, Berkshire Hathaway, Warren, StreetAccount, Andrew Mok, Sovos, Campbell, Sovos Brands, Campbell Soup, Morgan Stanley, Benjamin Swinburne, Oppenheimer, Yun Li, Alex Harring, Samantha Subin Organizations: Refinitiv, Berkshire, Warren, UBS, Sovos, PayPal, U.S, FactSet Locations: Gruenheide, Germany, BioNTech –, stablecoins, U.S

☆ Pickleball is bad news for health insurance stocks, UBS says
▼ + stars: | 2023-06-26 | by ( Jesse Pound | In Jesse-Pound | ) www.cnbc.com time to read: +1 min

A sport that is making many older Americans more active could be backfiring for health insurance companies, according to UBS. Pickleball is a tennis-adjacent sport that has exploded in popularity since the Covid-19 pandemic, attracting millions of new players and celebrity investors . "After analyzing the growth in pickleball as well as the nature and frequency of related injuries, we conducted a bottom-up analysis of medical costs. In total, we estimate $250-500 mn of medical costs directly attributable to pickleball and see potential for greater medical costs indirectly linked to pickleball," the note said. All said, we estimate that pickleball medical costs could be driving 5-10% of the unexpected medical cost trend this year," the note said.

Persons: Andrew Mok, Goldman Sachs, Mok, UNH, — CNBC's Michael Bloom Organizations: UBS, Pickleball, Insurance, Medicare Locations: pickleball, UnitedHealth, Friday's

☆ Analysts name the top 'high conviction' stocks for playing the market turbulence
▼ + stars: | 2022-09-24 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

CNBC Pro combed through top Wall Street research to find analysts' top "high conviction" ideas. With a Street high price target of $278, the stock is one of DA Davidson's top "high conviction" small cap ideas. DaVita The kidney and dialysis care provider was recently upgraded to a buy rating from neutral by investment firm UBS. UBS has a Street high price target of $117 per share, which implies a nearly 38% gain from the stock's current level. While a period of consolidation is possible, we have high conviction that CRWD is a unique investment vehicle as the modern security cloud, with exceptional long-term value creation potential."

Search resuls for: "Andrew Mok"

6 mentions found